Last reviewed · How we verify
Dexchlorpheniramine 1% gel
Dexchlorpheniramine is a selective H1-receptor antagonist that blocks histamine-mediated allergic and inflammatory responses in topical form.
Dexchlorpheniramine is a selective H1-receptor antagonist that blocks histamine-mediated allergic and inflammatory responses in topical form. Used for Allergic dermatitis and pruritus (topical), Urticaria and other allergic skin conditions (topical).
At a glance
| Generic name | Dexchlorpheniramine 1% gel |
|---|---|
| Sponsor | Mantecorp Industria Quimica e Farmaceutica Ltd. |
| Drug class | H1-receptor antagonist (first-generation antihistamine) |
| Target | H1 histamine receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology / Allergy |
| Phase | Phase 3 |
Mechanism of action
As a first-generation antihistamine, dexchlorpheniramine competitively antagonizes H1 histamine receptors, preventing histamine from binding and triggering allergic symptoms such as itching, urticaria, and inflammation. When formulated as a 1% gel, it provides localized topical delivery to affected skin areas, reducing systemic absorption and side effects while targeting cutaneous allergic reactions directly.
Approved indications
- Allergic dermatitis and pruritus (topical)
- Urticaria and other allergic skin conditions (topical)
Common side effects
- Local skin irritation or burning
- Drowsiness (if systemic absorption occurs)
- Contact dermatitis
Key clinical trials
- Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer (PHASE4)
- Non-inferiority Clinical Trial of Dexchlorpheniramine (Cream Versus Gel) in the Relief of Sunburn Related Symptoms (PHASE3)
- Comparative Study of Two Forms of Topical Dexchlorpheniramine Maleate (Cream Versus Gel) for Insect Bites (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: